APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.
12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.
Thanks to its property to create a microenvironment which is favorable for wound healing, unfavorable
to the pathogens growth, Bio'n can be expected to act vs. Propionibacterium acnes and to improve the
skin healing process, helping to decrease the incidence of post-acne scarring.
Complete
Non confidential
Opportunity
Profile
> Antimicrobial activity demonstrated in vitro vs. Propionibacterium acnes
> Improvement of wound healing demonstrated in a rabbit pre-clinical model: Bio’n
induces a rapid wound closure; the histological evaluation shows a good effect of Bio’n
on skin neo-angiogenesis and extra-cellular matrix deposition.
